Cargando…

Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents

Cholestatic liver disease is a disease that causes liver damage and fibrosis owing to bile stasis. It is represented by primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), but the pathophysiological pathways that cause bile stasis in both diseases are different. The pathogene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasegawa, Sho, Yoneda, Masato, Kurita, Yusuke, Nogami, Asako, Honda, Yasushi, Hosono, Kunihiro, Nakajima, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282588/ https://www.ncbi.nlm.nih.gov/pubmed/34142342 http://dx.doi.org/10.1007/s40265-021-01545-7

Ejemplares similares

Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan
por: Yoneda, Masato, et al.
Publicado: (2021)

Current Research on the Pathogenesis of NAFLD/NASH and the Gut–Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome
por: Kobayashi, Takashi, et al.
Publicado: (2022)

Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD
por: Nogami, Asako, et al.
Publicado: (2022)

The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target
por: Kessoku, Takaomi, et al.
Publicado: (2021)

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
por: Nogami, Asako, et al.
Publicado: (2023)

Involvement of Periodontal Disease in the Pathogenesis and Exacerbation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Review
por: Kobayashi, Takashi, et al.
Publicado: (2023)

Single-balloon-assisted endoscopy with peroral pancreatoscopy and electrohydraulic lithotripsy
por: Yagi, Shin, et al.
Publicado: (2022)

A safe needle-knife precut papillotomy technique in a patient with a naïve papilla and surgically altered anatomy
por: Hosono, Kunihiro, et al.
Publicado: (2022)

Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care
por: Yoneda, Masato, et al.
Publicado: (2023)

Learning Curve of Endoscopic Retrograde Cholangiopancreatography Using Single-Balloon Enteroscopy
por: Hosono, Kunihiro, et al.
Publicado: (2022)

Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Hasegawa, Sho, et al.
Publicado: (2020)

Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Honda, Yasushi, et al.
Publicado: (2020)

Utility of Fine-Gauge Balloon Catheter for EUS-Guided Hepaticogastrostomy
por: Yagi, Shin, et al.
Publicado: (2022)

Three-dimensional analysis of pancreatic fat by fat-water magnetic resonance imaging provides detailed characterization of pancreatic steatosis with improved reproducibility
por: Kato, Shingo, et al.
Publicado: (2019)

Endotoxins and Non-Alcoholic Fatty Liver Disease
por: Kessoku, Takaomi, et al.
Publicado: (2021)

Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
por: Yoneda, Masato, et al.
Publicado: (2022)

Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease
por: Kawamura, Nobuyoshi, et al.
Publicado: (2022)

Gastroesophageal varices evaluation using spleen‐dedicated stiffness measurement by vibration‐controlled transient elastography
por: Nagai, Koki, et al.
Publicado: (2021)

Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved
por: Yoneda, Masato, et al.
Publicado: (2023)

Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM
por: Kobayashi, Takashi, et al.
Publicado: (2023)

A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs
por: Kobayashi, Takashi, et al.
Publicado: (2022)

Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study
por: Iwaki, Michihiro, et al.
Publicado: (2022)

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
por: Yoneda, Masato, et al.
Publicado: (2021)

Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs
por: Tomeno, Wataru, et al.
Publicado: (2020)

Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Franseen Needles May Be Promising for Improving the Sampling Adequacy of EUS-FNA for Subepithelial Lesions
por: Kasuga, Noriki, et al.
Publicado: (2022)

Comparison of long‐term prognosis between non‐obese and obese patients with non‐alcoholic fatty liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2022)

Current Therapies for Cholestatic Diseases
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2023)

Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study
por: Kasai, Yuki, et al.
Publicado: (2022)

Current and future therapies for inherited cholestatic liver diseases
por: van der Woerd, Wendy L, et al.
Publicado: (2017)

Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype
por: Kessoku, Takaomi, et al.
Publicado: (2020)

Intravenous injection of low-dose flurbiprofen axetil for preventing post-ERCP pancreatitis in high-risk patients: An interim analysis of the trial
por: Fujita, Yuji, et al.
Publicado: (2016)

Novel therapeutic targets for cholestatic and fatty liver disease
por: Trauner, Michael, et al.
Publicado: (2022)

Diagnosing malignant distal bile duct obstruction using artificial intelligence based on clinical biomarkers
por: Sugimoto, Yuichi, et al.
Publicado: (2023)

Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms
por: Kurita, Yusuke, et al.
Publicado: (2022)

Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma
por: Kurokawa, Suguru, et al.
Publicado: (2022)

Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors
por: Hasegawa, Sho, et al.
Publicado: (2022)

The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities
por: Mazzetti, Marta, et al.
Publicado: (2021)

Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases
por: Zhang, Fangling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_84v2nv9ipjhv2namok0phaqfa9